Get started

Signalservice

Hellena | EUR/USD (4H): Short to Support area 1.02539.Dear Colleagues, due to the recent sharp price movement, I have redrawn the waves and now I see the completion of the five-wave impulse in the wave “5” of higher order. I expect that the price should update the nearest local minimum of the wave “3” 1.03350. I expect the price to reach at least the area of 1.02539. Manage your capital correctly and competently! Only enter trades based on reliable patterns!
Short
by Hellena_Trade
11
Lingrid | GOLD Potential EXIT from the CONSOLIDATION ZoneOANDA:XAUUSD moved higher and is currently testing the previous week's high. It has broken out of the consolidation zone, and notably, the price has also broken and closed above a trendline that acted as a resistance zone for more than three weeks. I believe the price is targeting a retest of the weekly high at 2,665. However, I anticipate that the market may experience a pullback before continuing its upward trajectory. Looking left on the chart, we can see that the price has bounced off this support level several times in the past, reinforcing its significance. Therefore, it would be prudent to wait for confirmation of further movement. My goal is resistance zone around 2663 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
OANDA:XAUUSDLong
by Lingrid
20
Lingrid | EURCAD Capitalize on SIDEWAYS movementThe price perfectly fulfilled my last idea. It hit the target. FX:EURCAD market is currently moving sideways. On the daily timeframe, the price recently reached a strong resistance zone and then pulled back after creating a double top. Following five consecutive bullish weeks, I believe the market is due for a pullback. I anticipate that the price will reject the resistance zone around 1.49500 and the downward trendline, leading to further sideways movement. My goal is support zone around 1.48800 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Short
by Lingrid
1
Lingrid | EURUSD trend CONTINUATION from RESISTANCEThe price perfectly fulfilled my last idea. It hit the target. FX:EURUSD market fell and reached the weekly level. It broke below the upward trendline and then continued to move lower. Essentially, the price action formed a descending triangle pattern before dropping, presenting a trend continuation opportunity. I believe the price will break below the weekly low to retest the psychological level below. My goal is support zone around 1.03000 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Short
by Lingrid
12
Ai16Z | From Meme to Money making machineai16z is the new star in the meme token galaxy, built on the lightning fast Solana blockchain and launched on the playful daos. fun platform. With AI backing it and a cheeky nod to the a16z VC fund, this token’s got serious meme mentum. Today’s Price Check -Current Price: $1.27 (+5% in the last 24 hours) -All-Time High (ATH): $1.38 (hit on Dec 29, 2024) – just 5.86% below the peak. -Circulating Supply: 1.10 billion tokens (max supply also 1.10 billion). -24-Hour Trading Volume: A whopping $75.84 million. Market Flex ai16z is traded on 24 markets and 14 exchanges, with Gate.io leading the pack. It holds a cozy 0.04% share of the total crypto market, boasting a market cap of $1.43 billion. Oh, and word on the street? It’s on Binance’s radar for a potential listing Riding the Meme Wave Move over, SHIB, PEPE, and DOGE—ai16z is stealing the spotlight in the meme coin market rally. Its lowest price ever? A humble $0.01019 on Nov 3, 2024. Fast forward to now, and it’s up an insane 12,650% from that rock bottom price. The Whale Tale December 28 was a big day for ai16z, thanks to a crypto whale who made some serious moves. This savvy investor withdrew 10M USDC from Coinbase and snagged 13.16M ai16z tokens when they were undervalued on Dec 11. The result? In just two weeks, their $10 million investment ballooned to a jaw-dropping $15.66 million, netting a sweet $5.66 million profit. That’s the kind of whale flex you all dream about. ai16z is proving it’s more than just a meme, it’s a mover and shaker in the Solana ecosystem.
Long
by moonypto
2
Lingrid | GOLD channel BREAKOUT. Short from RESISTANCE zoneOANDA:XAUUSD market dipped below the 2600 support level before bouncing back to test the resistance zone. It also broke and closed below the upward channel. Now, the price is near a swap zone where it has changed direction multiple times. I think the market will keep pushing down from here and will likely retest the recent support level. Since the price has fallen from this level before, there's a good chance it will do so again. I expect the price to continue consolidating and retest the support level following the rebound. My goal is support level ay 2600 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
OANDA:XAUUSDShort
by Lingrid
9
Act/UsdtBINANCE:ACTUSDT ### 📈 **Price Trend** - The price is currently **pushing upwards** 📈. It’s trying to break through certain **resistance levels**. If it continues moving upwards and successfully holds, it could reach higher price points. --- ### 🔴 **Resistance Levels (Where Price May Face Difficulty Going Higher)** 1. **0.300** 🚫: This is the first **resistance level**, meaning the price could face difficulty breaking through here. If the price reaches this point, sellers might step in, pushing the price back down. 2. **0.3480** 🚫: The next key resistance level. If the price manages to break above 0.300, it could face further challenges at 0.3480. This is another level where the price might stall or reverse. 3. **0.4016** 🚫: The **highest resistance** in this scenario. If the price breaks both 0.300 and 0.3480, 0.4016 would be the next significant level to watch. Reaching this level would suggest strong upward momentum, but also increase the chances of a pullback due to selling pressure. --- ### 🟢 **Support Level (Where Price Has a Strong Base)** - **0.2400** 🔑: This is the **support level**, which is where buyers are likely to step in and prevent the price from dropping further. If the price falls to this level, it’s expected to find buying interest and potentially bounce back up. It’s an area of price stability, and as long as it holds above this level, the upward trend could continue. --- ### ⚠️ **Important Note (Not Financial Advice)** - This information is for educational and illustrative purposes only. It’s important to conduct your own research or consult a financial advisor before making any decisions based on price levels and trends. Every market can be unpredictable!
Long
by Wolftrader1337
Ai & OnChain Opportunities | Crypto insights for 2025How Base, Ai & Pump Fun Will Shape the Crypto Market in 2025 2024: A Milestone Year for On-Chain Growth The year 2024 may prove pivotal for onchain development, potentially rivaling the "DeFi Summer." Narrative driven investment opportunities are expected to proliferate, fueled by the widespread adoption of the “everything can be a Meme” concept and the rapid asset issuance popularized by Pump Fun. Meme projects can now launch without requiring top tier centralized exchange (CEX) listings, with market caps in the onchain space reaching approximately $1 billion. This presents significant profit opportunities for ordinary users, with toptier CEXs serving as the final stage for cashing out on-chain investments. Challenges for Established Assets Rising tensions between VCCoin and its community have led to underperformance for new assets listed on major CEXs, while older projects struggle to stay relevant. Many such projects lack motivation or fail to adapt to market changes, often adopting a passive strategy while awaiting unlock periods. Key Predictions for 2025 1. DEX/CEX Monthly Volume Ratio to Exceed 20% In December 2024, decentralized exchange (DEX) trading volumes hit a record $320 billion, marking over 200% year-over-year growth. The DEX/CEX ratio rose from 9.6% in December 2023 to 11.7%, peaking at 13.9% during the year. Continued improvements in Web3 wallets and on-chain tools, spearheaded by CEXs, along with the growing appeal of the Meme sector, are expected to accelerate user migration from CEXs to DEXs. 2. AI Agents/AI Meme Market Cap to Eclipse NFTs AI Agents integrated with tokenization have emerged as the fastest-growing narrative, with the total market cap for related tokens reaching $12 billion. Frameworks like ai16z’s Eliza and Virtuals Protocol’s Game Framework have gained dominance, enabling rapid deployment of AI Agent tokens. Virtuals Protocol’s VIRTUAL token leads the sector with a $3.5 billion market cap, bolstered by a robust ecosystem of subtokens. 3. Emergence of Vertical Launch Platforms The success of Pump Fun on Solana, a low-cost launchpad for issuing Memecoins, has inspired similar platforms across other networks. Specialized vertical platforms like vvaifu (AI Agents) and Pump Science (DeSci) are gaining traction. The expansion of the “everything can be a Meme” narrative is expected to drive demand for more niche launchpads. 4. Base Ecosystem Tokens to Debut on Binance The Base network, an Ethereum Layer 2 developed under Coinbase, is predicted to have at least five native tokens listed on Binance’s spot market. With a concentrated ecosystem led by Virtuals and Farcaster, Base is positioned as a key contender for listings. Integration with Coinbase Wallet and the potential for favorable U.S. policies could enhance its competitive edge. 5. Hyperliquid’s Spot Market to Drive Wealth Effects Hyperliquid, leveraging its HYPE token airdrops and novel asset standards (HIP1 and HIP2), is positioned to create exclusive wealth-generation opportunities. Projects like Solv Protocol and Azuki   Anime have utilized its spot listing auctions, attracting significant interest. HYPE’s value, while substantial, will benefit from increased trading volume and partnerships with exclusive projects. These projections reflect growing innovation in onchain development, with decentralized finance, AI tokenization, and specialized launchpads driving the next phase of market evolution.
Long
by moonypto
TEVA Pharmaceutical is a BUY?As the excitement around AI continues to wane, concerns about a potential US recession grow, and the risks of a major conflict in the Middle East linger, Teva Pharmaceutical's stock is entering an accumulation phase above $18, signaling strong bullish sentiment. Why Wall Street's bullish in this drug company ? First, on July 31, Teva announced its financial results for the second quarter of 2024, demonstrating that the company remains resilient despite years of investor disappointment following the Allergan Generics acquisition and the loss of Copaxone exclusivity. However, over the past 18 months, under Richard Francis' leadership, the company has shown significant growth, with increasing revenue and profits in its European and US segments, the successful launch of biosimilars and Uzedy, and record sales of Austedo, its blockbuster treatment for certain neurological disorders. Alongside rising sales of generics, Teva has also accelerated the development of innovative medications, which could set new standards in treating schizophrenia and some chronic inflammatory diseases. For instance, on July 25, the company delighted investors by announcing that it had completed patient enrollment ahead of schedule in a Phase 2b clinical trial assessing the efficacy and safety of duvakitug for treating ulcerative colitis and Crohn's disease, driven by strong interest from healthcare professionals and patients. Teva Pharmaceutical's financial performance and 2024 outlook After years of challenges, the Teva revenue exceeded $4 billion once again, reaching $4.14 billion in the second quarter of 2024, a 7.4% year-on-year increase that surpassed consensus estimates by $114 million. Meanwhile, another critical financial metric, earnings per share aka EPS, exceeded my expectations despite rising costs associated with conducting expensive clinical trials for assessing the efficacy of Teva's biosimilars and experimental drugs targeting neurodegenerative and autoimmune disorders. The Israeli company's EPS reached $0.61 for the three months ending June 30, 2024, marking a 27.1% increase from the previous quarter and surpassing analysts' forecasts by six cents. What factors contribute to Teva Pharmaceutical's success? To answer this objectively, it's essential to examine not only the impact of sales from individual medications but also to delve deeper into how effectively the company's management is handling the development of each of Teva's business segments. We'll begin with the United States segment, which significantly influences Teva's financial standing. For the three months ending June 30, 2024, revenue in this segment reached $2.12 billion, reflecting an 11.5% year on year increase and a 22.3% rise from the previous quarter. First, Teva's revenue and profit growth were largely fueled by significant advancements in its generics business, despite facing stiff competition from companies like Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Perrigo (PRGO), and others in the market. In the second quarter, total sales of generic products reached approximately $1.03 billion, marking a 26.6% increase from the previous quarter. What factors led to the recovery of Teva's generics business? The resurgence of Teva's generics business in the U.S. was primarily driven by the launch of an interchangeable biosimilar to AbbVie's Humira (ABBV), rising demand for generic versions of Bristol-Myers Squibb's Revlimid (BMY), a major blockbuster for treating multiple myeloma, the generic version of Novo Nordisk's Victoza (NVO) for type 2 diabetes, and the expansion of its drug portfolio. The soaring sales of Copaxone and the strong performance of Austedo, which I analyzed in detail in a previous article, were also notable. Despite increasing competition in the U.S. tardive dyskinesia therapeutics market from Neurocrine Biosciences' (NBIX) Ingrezza, Austedo's demand continued to grow. Sales of the Austedo franchise reached $407 million in the second quarter of 2024, a 32.1% YOY increase, driven by expanded patient access and the FDA's late May approval of Austedo XR in four new tablet strengths, giving doctors more options for optimizing treatment regimens for adults with tardive dyskinesia and Huntington's disease-associated chorea. I also want to highlight Uzedy, a long-acting formulation of risperidone, as another key contributor to Teva's revenue growth. Although the company launched Uzedy in May 2023 and has not yet disclosed its sales figures, it has been approved for the treatment of schizophrenia. However, as evident from the chart below, the total number of prescriptions has been steadily increasing month over month. Teva Pharmaceutical estimates that its revenue from Uzedy will be around $80 million in 2024, exceeding my expectations by approximately $25 million. Despite ongoing growth in demand for this anti-CGRP migraine medication, its sales amounted to $42 million in the second quarter of 2024, a decrease of 6.7% compared to the previous quarter and 19.2% year-on-year. This decline was primarily due to an increase in sales allowances linked to a one-time event. Now, let's turn our attention to the company's Europe segment, which generates most of its revenue through sales of generics and biosimilars. For the three months ending June 30, 2024, sales in this segment reached approximately $1.21 billion, reflecting a 4.3% year-on-year increase, driven by new product launches and growing demand for Ajovy. However, sales of respiratory medications continue to face challenges due to a decline in cold and flu cases. As anticipated, demand for Copaxone is weakening, not only because of competition from generic versions but also due to the availability of more effective treatments for relapsing forms of multiple sclerosis, such as Bristol-Myers Squibb's Zeposia, Roche Holding's Ocrevus and TG Therapeutics' Briumvi (TGTX). Lastly, let's discuss the International Markets segment, which focuses on commercializing Teva's drugs across 35 countries, including Canada and Japan. In the second quarter, revenue for this segment was $593 million, representing a 2.6% YOY increase. However, the segment's profit dropped significantly to $73 million quarter over quarter, due to declining demand for Copaxone, increased R&D expenses, and higher sales and marketing costs related to the distribution of Austedo in China. The question arises: "Are there any positives?" The short answer is yes. Teva's revenue from generic drugs has been on an upward trend in recent years, with the exception of the fourth quarter of 2023. For the three months ending June 30, 2024, it reached $488 million, marking a 2% increase from the previous quarter. What is driving this sales growth? Despite challenges such as the weakening of foreign currencies like the Japanese yen, ruble, and Chinese yuan against the US dollar, increased competition in Japan, and ongoing inflationary pressures on the pharmaceutical industry, Teva’s management has successfully navigated these obstacles by expanding its medication portfolio and raising prices. Now lets talk about Risks Several risks could negatively impact Teva Pharmaceutical’s investment appeal in the medium to long term. At the end of July, Teva reported financial results for the second quarter of 2024, which not only exceeded analysts' expectations but also reinforced confidence in the effectiveness of the business strategies implemented by CEO Richard Francis. In addition to accelerating the recovery of the company's generics business, boosting sales of Austedo and Uzedy, and launching the Humira biosimilar in May, Teva also raised its full-year 2024 guidance. With a P/E ratio of 6.35x, which suggests the stock is trading at a discount compared to the broader healthcare sector, other positives include the reduction of Teva’s net debt by about $2 billion over the past 12 months, as well as year-over-year growth in gross and operating profits. To understand who truly holds control over Teva Pharmaceutical Industries Limited, it's crucial to examine the company's ownership structure. The largest share of ownership, approximately 69%, is held by institutional investors. This means that this group stands to experience the greatest potential for gains or losses, depending on the company's performance. The company has also accelerated the development of its product candidates under its "Pivot to Growth" program, which aims to strengthen its balance sheet and enhance its investment appeal by expanding its biosimilar portfolio and bringing potential best-in-class drugs for cancer, neurological, and autoimmune disorders to market. So TEVA Pharmaceutical is a BUY? YUP
NYSE:TEVALong
by moonypto
DOGE & ELON The price of Dogecoin is $0.09 today with a 24hour trading volume of 770 million dollar . This represents a 10% price increase since last week and 22% price increase since last month Musk's tweet offering 1 million Dogecoin to anyone who could prove ownership of an emerald mine has led to gains of 4.9% and who can forget when he changed the Twitter logo to feature the Shiba Inu dog, which caused another 30% pump while Dogecoin's technical structure is bullish, there is a lack of buying pressure behind the coin. traders should be cautious and consider waiting for a break in structure on lower timeframes before seeking to enter short positions. daily active addresses have increased as social media buzzed about Dogecoin, but the 90-day mean coin age has been sliding downward since mid-March. Dogecoin bounced off the moving averages on April 12, as seen from the long tail on the day’s candlestick. The bulls tried to drive the DOGE/USDT pair above the 38.2% Fibonacci retracement level of $0.09 but the bears did not budge. This suggests that the sentiment remains negative and traders are selling on rallies. Buyers must push and sustain the price above $0.09 to indicate that the selling pressure may be reduced. The pair may then ascend to the 61.8% retracement level of $0.10. Usually, a break and close above this level results in a 100% retracement. If that happens, the pair may soar to $0.11.
by moonypto
11
Btc/UsdtBITSTAMP:BTCUSD The current price of Bitcoin is $94,242, and the market is at a critical juncture. 🔍 Support and Resistance Levels 1. Support at $94,242: If Bitcoin holds this level, it could signify strong buying pressure. Traders often see this as a crucial area for bulls to defend. Holding above $94,242 could encourage more buyers to enter, fueling the next leg upward. 2. Next Support at $85,000: If Bitcoin breaks below $94,242, the next key support level is $85,000. This level represents a significant area where buyers may step in to prevent further decline. A drop to this level might shake weak hands but also attract long-term investors looking for a discount. 📈 Resistance Levels 1. Resistance at $100,000: If Bitcoin holds $94,242 and the bulls take control, the next target is the psychological and technical resistance at $100,000. This level is highly significant because it’s a round number that could trigger profit-taking by some traders. Breaking this resistance could pave the way for even higher levels. 💡 Summary • If Bitcoin holds $94,242 → next resistance: $100,000 🚀 • If Bitcoin breaks below $94,242 → next support: $85,000 📉 ⚠️ Not financial advice! Always do your research before making trading decisions and manage your risk wisely.
BITSTAMP:BTCUSDLong
by Wolftrader1337
Lingrid | EURUSD Intraday Selling OPPORTUNITY The price perfectly fulfilled my last idea. It hit the target. FX:EURUSD made a downward impulse move, creating a large bearish candle. The market is currently consolidating, providing an opportunity to take advantage of its sideways movement. It is rolling back towards a resistance zone and an upward trendline. Looking left, we see that the price has bounced off this area twice before, so it could potentially rebound again given the current sideways trend. I expect the price to reject the resistance zone, leading to a decline. My goal is support zone around 1.03800 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Short
by Lingrid
5
Lingrid | SUIUSDT possible Sell-Off at the Dawn of 2025BINANCE:SUIUSDT is currently consolidating after reaching the psychological level at 5.00. It’s been moving back and forth, forming lower highs while bouncing off the trendline. The last two weeks of December and the first two weeks of January were characterized by sideways movement last year, and it appears we may be experiencing a similar situation now. It’s important to note that there was a strong bullish impulse leg before, but the price failed to continue moving higher, indicating a lack of bullish momentum to sustain that upward movement. This suggests that we might see some bearish action in the near term, potentially setting the stage for a stronger bullish move later on. I expect the market to retest at least channel border. My goal is support zone around 3.61 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Short
by Lingrid
5
Lingrid | EURUSD continues to SEE ConsolidationLast week, FX:EURUSD bounced off the resistance zone at 1.04400 and moved lower, but it didn’t have enough bearish momentum to keep going down. Instead, it returned to the level it was at the previous Monday, creating an equal high. I believe the market will push a little higher before pulling back and continuing its bearish move. However, since many markets are in consolidation due to the holidays, there's a chance this week could be another sideways week. Nevertheless, I expect the price to rise above the EQHs before eventually falling. My goal is support zone around 1.03830 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Short
by Lingrid
2
Lingrid | Gold Weekly Market Outlook: Ongoing ConsolidationOANDA:XAUUSD market spent another week in the consolidation zone, oscillating between key levels before bouncing off 2630 and pulling back. During the holiday-shortened week, trading volume was naturally reduced, and the market is now testing a crucial support level. The current market structure suggests a slightly bearish sentiment, particularly after breaking and closing below the previous higher low at 2605 last week. On the weekly timeframe, price action formed another doji candle, suggesting a potential breakout from either its high or low next week. Price continues to trade within the previous week's range between 2585 and 2665. The final monthly candle of 2024 may close as a bearish candle with a long tail, indicating the possibility of a deeper pullback. With relatively few high-impact news next week, the market is likely to continue moving sideways for the next couple of weeks. We can expect increased market noise until we see a clear trend. However, if price breaks below the previous support at 2585, the price may drop to 2500. While the long-term uptrend remains intact, the market appears poised for a continued pullback in the short term. Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
OANDA:XAUUSDShort
by Lingrid
12
Lingrid | BITCOIN complex PULLBACK in the MARKETBINANCE:BTCUSDT is forming a complex ABCD pullback. The price continues to stay below the key level of $100,000, and it has created a range zone with equal lows. Notably, there is a structure shelf around $91,000, where the price has consistently bounced back. On the weekly timeframe, we've seen a bearish long-tailed bar, suggesting that the price may retest $85,000. At the start of 2025, we might experience some market shakeouts, so I expect a deeper pullback before rebounding off the support level, potentially taking liquidity below the structure support. My goal is resistance zone around 98,000 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Long
by Lingrid
1